Altimmune, Inc. · NASDAQ:ALT
Altimmune — Pharmathene — Rodman & Renshaw 14th Annual Healthcare Conference 2012
21 slides from Altimmune's conference presentation, Sep 10, 2012
Slide 1: Rodman & Renshaw 14th Annual Healthcare Conference
1 Rodman & Renshaw 14 th Annual Healthcare Conference September 10, 2012
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . This information may involve known and unknown risks, uncertainties an
Slide 3: PharmAthene Investment Highlights
3 PharmAthene Investment Highlights • Leading biodefense company with diversified portfolio of medical countermeasures against biological and chemical threats • Large and federally mandated multi - billion dollar biodefense market • Pipeline addresses major threats - unmet national stockpiling requi
Slide 4: Biodefense Industry: A Critical Component of National Security
4 Biodefense Industry: A Critical Component of National Security • Project BioShield legislation signed in 2004 by congressional mandate • Enables U.S. Government to fund development and purchase of necessary medical countermeasures against leading threats – anthrax and smallpox and other agents • B
Slide 5: A Lower Risk Development Process: Earlier Product Delivery
5 A Lower Risk Development Process: Earlier Product Delivery Typical Biotech Development Process Biodefense Development Process Safe & Effective Safe & Effective Discovery Non - Clinical Development Sales Product Approval Discovery Pre - Clinical Phase 1 Phase 2 Phase 3 Product Approval Sales Time 8
Slide 6: Near-Term Revenue Generating Opportunities
6 Near - Term Revenue Generating Opportunities SparVax™ rPA Anthrax Vaccine Valortim ® (Bristol - Myers Squibb) Anthrax Anti - Toxin $ 1.2B 2015 - 2021 Sources: analyst reports; company estimates * Assumes full execution of “justification for other than full and open competition” notification initia
Slide 7: Anthrax Vaccine: Urgent Need for Next Generation Option
7 Anthrax Vaccine Urgent Need for Next Generation Option • Current requirement for national anthrax stockpile is 75M doses • Current vaccine (BioThrax ® ): 60 years old, uses antiquated and inefficient technology by today’s standards • Need for safer, more cost effective vaccine with enhanced produc
Slide 8: SparVax Leading Next Generation Anthrax Vaccine
8 SparVax™ Leading Next Generation Anthrax Vaccine • Highly purified recombinant p rotective antigen – Modern E. coli - based production • ~700 individuals in Phase I and Phase II clinical trials • Pre - and post - exposure protection • Enhanced convenience and cost - effectiveness (PEP regimen) – 3
Slide 9: Executing on SparVax Milestones
9 Executing on SparVax™ Milestones x Completed Technology Transfer x Successfully Established Manufacturing Process – Completed extensive assay development and qualification – Demonstrated 36 - month product stability – Successful commercial scale - up to 1500L engineering run – Completed first comm
Slide 10: SparVax Clinical Study Update
10 SparVax™ Clinical Study Update • PharmAthene notified the study was placed on clinical hold pending provision of additional stability data to FDA • PharmAthene to provide requested data as part of a full response to FDA clinical hold • Provision of data and ongoing discussions will determine timi
Slide 11: 3rd Generation rPA Anthrax Vaccine
11 3 rd Generation rPA Anthrax Vaccine • Government requirement – Enhanced stability – maintain stability for 3 years at 35ºC – Improved potency – induce protective immunity in 2 or fewer doses • PharmAthene’s 3 rd Generation rPA approach – rPA + adjuvant – Lyophilized rPA formulation – Potential pa
Slide 12: Valortim Anthrax Anti-Toxin
12 Valortim ® Anthrax Anti - Toxin • Dept. of Homeland Security Material Threat Assessment: 200,000 treatments • HHS active procurement program to fulfill requirement Fully human monoclonal antibody (MAb ) • Unique mechanism of action similar to natural immune response • Effective Pre - and Post - E
Slide 13: Anti-Toxin Market Opportunity
13 Anti - Toxin Market Opportunity • Unmet need: current treatment options for post exposure are inadequate – Vaccines are not optimal for use post - exposure – Antibiotics are not optimally effective in individuals with active, symptomatic anthrax • Valortim ® is well positioned for procurement – C
Slide 14: Smallpox Presents Grave Threat
14 Smallpox Presents Grave Threat • Smallpox designated a “material threat” to the U.S. in 2004 • Highly contagious virus is easy to conceal, transport and disperse • Current vaccine not a complete defense – Vaccination must occur pre - exposure or less than 4 days post - exposure – 4% of individual
Slide 15: ST-246 (Tecovirimat) - SIGA Technologies Leading Smallpox Antiviral
15 ST - 246 ® ( Tecovirimat ) - SIGA Technologies Leading Smallpox Antiviral Orally Administered Smallpox Antiviral Therapeutic ST - 246 ® ( Tecovirimat ) Product Profile • Antiviral for post - event prophylaxis, treatment of symptomatic individuals • Small molecule enables increased cost effectiven
Slide 16: PharmAthene Wins Significant Interest in ST-246 Revenue Stream
16 PharmAthene Wins Significant Interest in ST - 246 ® ( Tecovirimet ) Revenue Stream • Culmination of 5 + - year breach of contract lawsuit in PharmAthene’s favor • Court awarded PIP 50% net profits on ST - 246 WW sales for 10 years – After initial $40M in net profits goes to SIGA – PTHN awarded $2
Slide 17: Nerve Agent Bioscavenger rBChE
17 Nerve Agent Bioscavenger rBChE Nerve Agent Bioscavenger to Address Chemical Threats • Prevents damage from chemical nerve agents • Robust advanced expression system (AES) technology platform • $5.7M in DoD funding • Cell culture - based manufacturing • Scalable manufacturing process • Streamlined
Slide 18: Key 2012-2013 Events
18 2012 H1 H2 2013 H1 H2 Key 2012 - 2013 Events Confirmation of ST - 246 financial interest ST - 246 ® ( Tecovirimat ) appeal; legal briefs filed Provide add’l data to satisfy FDA request ST - 246 ® ( Tecovirimat ) Supreme Court appeal resolution Complete SparVax™ clinical lot fill Sales of ST - 246
Slide 19: Executive Leadership
19 Executive Leadership Eric I. Richman MedImmune , HealthCare Ventures President & Chief Executive Officer Linda L. Chang Human Genome Sciences, Booz Allen & Hamilton SVP, Chief Financial Officer Francesca Cook Guilford, Covance, US Senate, DHHS SVP, Policy & Government Affairs Thomas R. Fuerst, Ph
Slide 20: Financial Summary
20 Financial Summary • As of June 30, 2012 • Cash, cash equivalents, U.S. government receivables: $20.0M • Q2 2012 Revenue: $6.3M • Q2 operating expenses decreased 18% year - over - year • On track to achieve stated objective of reducing cash burn to approx $6.0 million in 2012 • Company financed th
Slide 21: PharmAthene Investment Highlights
21 PharmAthene Investment Highlights • Leading biodefense company with diversified portfolio of vital medical countermeasures – Up to >$600M in U.S. Government funding to date* – Differentiated next - generation products • Infrastructure to support Government biodefense needs – Potential for signifi
Pharmathene — Rodman & Renshaw 14th Annual Healthcare Conference 2012 on 6ix